Often times with share prices of good companies, the early investors may end up waiting a long long time before the rest of the market catches on (and potentially lots of dips in their investments along the way).
The thing is - in the early days, good/bad companies may often share similar characteristics, and so it's not immediately obvious. Looking at the future of medical devices and healthcare, and given John's no-BS approach, I still feel AT1 is in a very good position, but this could take a few years yet to gain traction.
Yes revenue may not be shooting out the lights, and yes Atomo isn't currently signing contracts left right and center. But these things don't just appear right away either. Takes time.
Also note, many of the selling is done by retail investors to date. If institutions dumped their holdings, then there actually won't be sufficient bids on the buy side to even absorb their selling (share price will tank a lot more).
AT1 Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
